Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

Nicholas C. Turner(Royal Marsden NHS Foundation Trust), Alistair Ring(Brighton and Sussex Medical School), David Cameron(Edinburgh Cancer Research), Belinda Kingston(Breast Cancer Now), Michael Hubank(University College London), Ros Cutts(Institute of Cancer Research), Daniel Rea(University Hospitals Birmingham NHS Foundation Trust), Mark Tuthill(Oxford University Hospitals NHS Trust), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Heidrun Gevensleben(University Hospital Bonn), Rebecca Roylance(University College London Hospitals NHS Foundation Trust), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Peter Stephens(Royal Devon & Exeter NHS Foundation Trust), Hannah Bye(Royal Marsden NHS Foundation Trust), Lucy Kilburn(Institute of Cancer Research), Sarah Kernaghan(Institute of Cancer Research), Laura Moretti(Institute of Cancer Research), Andrew Wardley(The Christie Hospital), Claire Snowdon(Institute of Cancer Research), Richard D. Baird(Cancer Research UK), Matthew Winter(Weston Park Cancer Centre), Sue Martin(Institute of Cancer Research), Olga Oikonomidou(Western General Hospital), Katie Wilkinson(Institute of Cancer Research), Jacinta Abraham(Velindre NHS Trust), Abeer M. Shaaban(University Hospitals Birmingham NHS Foundation Trust), Katrina Randle(The Patients Association), Judith M. Bliss(Institute of Cancer Research)
The Lancet Oncology
September 10, 2020
10.1016/s1470-2045(20)30444-7
Cited by 351

Related Papers

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k